Bain Capital Life Sciences Investors, LLC Savara Inc Transaction History
Bain Capital Life Sciences Investors, LLC
- $298 Million
- Q1 2025
A detailed history of Bain Capital Life Sciences Investors, LLC transactions in Savara Inc stock. As of the latest transaction made, Bain Capital Life Sciences Investors, LLC holds 17,600,621 shares of SVRA stock, worth $35 Million. This represents 16.36% of its overall portfolio holdings.
Number of Shares
17,600,621
Previous 14,565,457
20.84%
Holding current value
$35 Million
Previous $44.7 Million
9.03%
% of portfolio
16.36%
Previous 12.07%
Shares
5 transactions
Others Institutions Holding SVRA
# of Institutions
143Shares Held
162MCall Options Held
54.8KPut Options Held
4.1K-
Nea Management Company, LLC Timonium, MD24.5MShares$48.7 Million6.43% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA12.4MShares$24.6 Million8.25% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA11.5MShares$22.8 Million2.0% of portfolio
-
Vestal Point Capital, LP New York, NY11MShares$21.9 Million2.18% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.12MShares$16.2 Million0.0% of portfolio
About Savara Inc
- Ticker SVRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 114,043,000
- Market Cap $227M
- Description
- Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.